Kronos Bio (KRON) Stock Forecast, Price Target & Predictions
KRON Stock Forecast
Kronos Bio stock forecast is as follows: an average price target of $1.00 (represents a -1.96% downside from KRON’s last price of $1.02) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
KRON Price Target
The average price target for Kronos Bio (KRON) is $1.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential -1.96% downside from KRON's last price of $1.02.
KRON Analyst Ratings
According to 5 Wall Street analysts, Kronos Bio's rating consensus is 'Buy'. The analyst rating breakdown for KRON stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kronos Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | Tyler Van Buren | Piper Sandler | $1.00 | $0.88 | 13.62% | -1.96% |
| May 03, 2024 | Robert Burns | H.C. Wainwright | $2.25 | $1.03 | 118.45% | 120.59% |
| May 23, 2022 | Piper Sandler | $13.00 | $3.81 | 241.21% | 1174.51% |
The latest Kronos Bio stock forecast, released on Nov 14, 2024 by Tyler Van Buren from Piper Sandler, set a price target of $1.00, which represents a 13.62% increase from the stock price at the time of the forecast ($0.88), and a -1.96% decrease from KRON last price ($1.02).
Kronos Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $1.00 | $1.63 |
| Last Closing Price | $1.02 | $1.02 | $1.02 |
| Upside/Downside | -100.00% | -1.96% | 59.80% |
In the current month, the average price target of Kronos Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kronos Bio's last price of $1.02. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 14, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Nov 14, 2024 | Cowen & Co. | Hold | Downgrade | |
| May 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 19, 2023 | Raymond James | Buy | Buy | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 23, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Feb 28, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Kronos Bio's last stock rating was published by Piper Sandler on Nov 14, 2024. The company Downgrade its KRON rating from "Overweight" to "Neutral".
Kronos Bio Financial Forecast
Kronos Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $2.29M | $917.00K | $1.86M | $1.22M |
| Avg Forecast | $333.33K | $333.33K | $333.33K | $1.17M | $2.42M | $2.10M | $1.52M | $1.00M | $1.52M | $1.40M | $1.67M | $5.63M |
| High Forecast | $333.33K | $333.33K | $333.33K | $1.17M | $2.42M | $2.10M | $1.52M | $1.00M | $2.03M | $1.40M | $1.67M | $5.63M |
| Low Forecast | $333.33K | $333.33K | $333.33K | $1.17M | $2.42M | $2.10M | $1.52M | $1.00M | $1.02M | $1.40M | $1.67M | $5.63M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.50% | 0.66% | 1.12% | 0.22% |
Kronos Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. KRON's average Quarter revenue forecast represents a -56.26% decrease compared to the company's last Quarter revenue of $2.29M (Dec 23).
Kronos Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-26.87M | $-33.83M | $-32.17M | $-28.49M |
| Avg Forecast | $200.00K | $200.00K | $200.00K | $700.00K | $1.45M | $1.26M | $915.00K | $600.00K | $915.00K | $840.00K | $1.00M | $3.38M |
| High Forecast | $200.00K | $200.00K | $200.00K | $700.00K | $1.45M | $1.26M | $915.00K | $600.00K | $1.22M | $840.00K | $1.00M | $3.38M |
| Low Forecast | $200.00K | $200.00K | $200.00K | $700.00K | $1.45M | $1.26M | $915.00K | $600.00K | $610.00K | $840.00K | $1.00M | $3.38M |
| Surprise % | - | - | - | - | - | - | - | - | -29.36% | -40.27% | -32.17% | -8.44% |
undefined analysts predict KRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kronos Bio's previous annual EBITDA (undefined) of $NaN.
Kronos Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-25.32M | $-31.37M | $-29.74M | $-23.41M |
| Avg Forecast | $-24.12M | $-18.09M | $-18.09M | $-18.09M | $-17.63M | $-16.74M | $-20.20M | $-25.48M | $-31.66M | $-30.91M | $-27.74M | $-26.84M |
| High Forecast | $-24.12M | $-18.09M | $-18.09M | $-18.09M | $-17.63M | $-16.74M | $-20.20M | $-25.48M | $-29.80M | $-30.91M | $-27.74M | $-26.84M |
| Low Forecast | $-24.12M | $-18.09M | $-18.09M | $-18.09M | $-17.63M | $-16.74M | $-20.20M | $-25.48M | $-32.91M | $-30.91M | $-27.74M | $-26.84M |
| Surprise % | - | - | - | - | - | - | - | - | 0.80% | 1.02% | 1.07% | 0.87% |
Kronos Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kronos Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $10.93M | $9.40M | $11.36M | $10.06M |
| Avg Forecast | $709.19K | $709.19K | $709.19K | $2.48M | $5.15M | $4.47M | $3.24M | $2.13M | $3.24M | $2.98M | $3.55M | $11.97M |
| High Forecast | $709.19K | $709.19K | $709.19K | $2.48M | $5.15M | $4.47M | $3.24M | $2.13M | $4.33M | $2.98M | $3.55M | $11.97M |
| Low Forecast | $709.19K | $709.19K | $709.19K | $2.48M | $5.15M | $4.47M | $3.24M | $2.13M | $2.16M | $2.98M | $3.55M | $11.97M |
| Surprise % | - | - | - | - | - | - | - | - | 3.37% | 3.16% | 3.20% | 0.84% |
Kronos Bio's average Quarter SG&A projection for Mar 24 is $2.13M, based on 1 Wall Street analysts, with a range of $2.13M to $2.13M. The forecast indicates a -80.53% fall compared to KRON last annual SG&A of $10.93M (Dec 23).
Kronos Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.43 | $-0.00 | $-0.52 | $-0.41 |
| Avg Forecast | $-0.40 | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.28 | $-0.34 | $-0.42 | $-0.53 | $-0.51 | $-0.46 | $-0.45 |
| High Forecast | $-0.40 | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.28 | $-0.34 | $-0.42 | $-0.49 | $-0.51 | $-0.46 | $-0.45 |
| Low Forecast | $-0.40 | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.28 | $-0.34 | $-0.42 | $-0.55 | $-0.51 | $-0.46 | $-0.45 |
| Surprise % | - | - | - | - | - | - | - | - | 0.82% | 0.00% | 1.13% | 0.92% |
According to undefined Wall Street analysts, Kronos Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KRON previous annual EPS of $NaN (undefined).
Kronos Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $0.86 | $10.00 | 1062.79% | Buy |
| LRMR | Larimar Therapeutics | $3.71 | $17.00 | 358.22% | Buy |
| CCCC | C4 Therapeutics | $3.59 | $16.00 | 345.68% | Buy |
| CTMX | CytomX Therapeutics | $0.82 | $3.47 | 323.17% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| ADXN | Addex Therapeutics | $7.56 | $30.00 | 296.83% | Buy |
| NXTC | NextCure | $0.80 | $3.00 | 275.00% | Buy |
| ERAS | Erasca | $1.84 | $6.00 | 226.09% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| ASMB | Assembly Biosciences | $13.86 | $35.50 | 156.13% | Buy |
| MRUS | Merus | $41.65 | $81.25 | 95.08% | Buy |
| ACHL | Achilles Therapeutics | $1.13 | $2.00 | 76.99% | Buy |
| CRNX | Crinetics Pharmaceuticals | $39.38 | $69.00 | 75.22% | Buy |
| LYEL | Lyell Immunopharma | $0.58 | $1.00 | 72.41% | Hold |
| REPL | Replimune Group | $14.07 | $23.00 | 63.47% | Buy |
| EWTX | Edgewise Therapeutics | $28.42 | $46.25 | 62.74% | Buy |
| KRON | Kronos Bio | $1.02 | $1.00 | -1.96% | Buy |